Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition.
Saved in:
| Title: | Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition. |
|---|---|
| Authors: | DuBose E; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Bevill SM; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Mitchell DK; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States., Sciaky N; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Golitz BT; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Dixon SAH; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States., Rhodes SD; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, United States.; Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Indiana University School of Medicine, Indianapolis, IN, United States., Bear JE; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Johnson GL; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States., Angus SP; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.; Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Indiana University School of Medicine, Indianapolis, IN, United States.; Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2024 May 16; Vol. 14, pp. 1191217. Date of Electronic Publication: 2024 May 16 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38854737 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22DuBose+E%22">DuBose E</searchLink>; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Bevill+SM%22">Bevill SM</searchLink>; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Mitchell+DK%22">Mitchell DK</searchLink>; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Sciaky+N%22">Sciaky N</searchLink>; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Golitz+BT%22">Golitz BT</searchLink>; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Dixon+SAH%22">Dixon SAH</searchLink>; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Rhodes+SD%22">Rhodes SD</searchLink>; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, United States.; Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Indiana University School of Medicine, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Bear+JE%22">Bear JE</searchLink>; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Johnson+GL%22">Johnson GL</searchLink>; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Angus+SP%22">Angus SP</searchLink>; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.; Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.; Division of Pediatric Hematology/Oncology/Stem Cell Transplant, Indiana University School of Medicine, Indianapolis, IN, United States.; Pharmacology & Toxicology, Indiana University School of Medicine, Indianapolis, IN, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2024 May 16; Vol. 14, pp. 1191217. <i>Date of Electronic Publication: </i>2024 May 16 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38854737 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fonc.2024.1191217 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1191217 Titles: – TitleFull: Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: DuBose E – PersonEntity: Name: NameFull: Bevill SM – PersonEntity: Name: NameFull: Mitchell DK – PersonEntity: Name: NameFull: Sciaky N – PersonEntity: Name: NameFull: Golitz BT – PersonEntity: Name: NameFull: Dixon SAH – PersonEntity: Name: NameFull: Rhodes SD – PersonEntity: Name: NameFull: Bear JE – PersonEntity: Name: NameFull: Johnson GL – PersonEntity: Name: NameFull: Angus SP IsPartOfRelationships: – BibEntity: Dates: – D: 16 M: 05 Text: 2024 May 16 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 2234-943X Numbering: – Type: volume Value: 14 Titles: – TitleFull: Frontiers in oncology Type: main |
| ResultId | 1 |
